NL-OMON28239招募中不适用
Randomized, double-blind, double-dummy, placebo-controlled, four-way crossover single dosestudy to determine the test-retest reliability of, and the effect of oral valproic acid, levetiracetam and lorazepam on, cortical excitability measurements in healthy volunteers as measured by TMS-EEG and TMS-EMG
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 16
研究概览
简要总结
A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis.
- •2. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum weight of 50 kg.
排除标准
- •1. Legal incapacity or inability to understand or comply with the requirements of the study.
- •2. Positive test for drugs of abuse at screening or pre-dose.
研究者
相似试验
尚未招募
不适用
PKPD of Oral vs IV S-Ketamine in HVNL-OMON28424CHDR16
进行中（未招募）
不适用
Randomised, double-blind, double-dummy, placebo-controlled,parallel group study to assess the efficacy and safety of 6 weeksof oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., orplacebo in symptomatic asthma patients on fluticasonepropionate MDISymptomatic asthmatic patients on inhaled corticosteroidsMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-014551-80-GBBoehringer Ingelheim Limited700
进行中（未招募）
不适用
Asthma patients symptomatic on treatment with an inhaled corticosteroid (fluticasone) are treated either with 400mg (4 capsules à 100mg) BI671800 twice daily, or 10mg (one capsule) Montelukast once daily, or placebo for 6 weeks. The three treatments are allocated to the patients at random in a double-blind, double-dummy fashion, so that neither the patient nor the investigator knows which of the three treatments the patient receives. The efficacy and safety of BI671800 is investigated.Symptomatic asthmatic patients on inhaled corticosteroidsMedDRA version: 13.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014551-80-DEBoehringer Ingelheim Pharma GmbH & Co. KG700
进行中（未招募）
1 期
Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat® Inhaler) and tiotropium bromide 18µg (oral inhalation, delivered by the HandiHaler®) after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-014418-86-DEBoehringer Ingelheim Pharma GmbH & Co. KG100
进行中（未招募）
不适用
Randomised, double-blind, double-dummy, placebo-controlled,parallel group study to assess the efficacy and safety of 6 weeksof oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., orplacebo in symptomatic asthma patients on fluticasonepropionate MDISymptomatic asthmatic patients on inhaled corticosteroidsMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-014551-80-SEBoehringer Ingelheim AB700